• Something wrong with this record ?

FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience

J. Hrudka, Z. Prouzová, K. Mydlíková, K. Jedličková, M. Holešta, A. Whitley, L. Havlůj

. 2021 ; 27 (-) : 1609756. [pub] 20210420

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22012469

Cholangiocarcinoma (CCA) is a liver malignancy associated with a poor prognosis. Its main subtypes are peripheral/intrahepatic and hilar/extrahepatic CCA. Several molecular, morphological and clinical similarities between hilar/extrahepatic CCA and pancreatic ductal adenocarcinoma (PDAC) have been described. FOXF1 is a transcription factor which has been described to have prognostic significance in various tumors and it is involved in the development of bile ducts. The aim of this study is to determine occurrence of nuclear expression of FOXF1 in both subtypes of CCA and metastatic PDAC and assess its potential usefulness as a diagnostic marker. Secondary aims were to investigate the use of C-reactive protein (CRP) immunohistochemistry for diagnosing intrahepatic peripheral CCA and the significance of histological features in CCA subtypes. 32 archive specimens of CCA, combined hepatocellular carcinoma-CCA (HCC-CCA) and liver metastasis of PDAC were stained by FOXF1 and CRP immunohistochemistry and evaluated to determine histological pattern. The CCAs were classified radiologically into peripheral/intrahepatic and hilar subtype. Using Fisher exact test, we identified nuclear FOXF1 as a fairly specific (87%) but insensitive (65%) marker of hilar and extrahepatic CCA and metastatic PDAC (p = 0.005). CRP immunohistochemistry was characterized by a high sensitivity and specificity, of 79% and 88%, respectively (p = 0.001). We did not identify any histomorphological features associated with either types of CCA or metastatic PDAC. As a conclusion of novel finding, FOXF1 immunohistochemistry may be regarded as a specific but insensitive marker of hilar/extrahepatic CCA and metastatic PDAC and it may help distinguish them from peripheral CCA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012469
003      
CZ-PrNML
005      
20220506131035.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/pore.2021.1609756 $2 doi
035    __
$a (PubMed)34257615
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hrudka, Jan $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Královské Vinohrady, Prague, Czech Republic
245    10
$a FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience / $c J. Hrudka, Z. Prouzová, K. Mydlíková, K. Jedličková, M. Holešta, A. Whitley, L. Havlůj
520    9_
$a Cholangiocarcinoma (CCA) is a liver malignancy associated with a poor prognosis. Its main subtypes are peripheral/intrahepatic and hilar/extrahepatic CCA. Several molecular, morphological and clinical similarities between hilar/extrahepatic CCA and pancreatic ductal adenocarcinoma (PDAC) have been described. FOXF1 is a transcription factor which has been described to have prognostic significance in various tumors and it is involved in the development of bile ducts. The aim of this study is to determine occurrence of nuclear expression of FOXF1 in both subtypes of CCA and metastatic PDAC and assess its potential usefulness as a diagnostic marker. Secondary aims were to investigate the use of C-reactive protein (CRP) immunohistochemistry for diagnosing intrahepatic peripheral CCA and the significance of histological features in CCA subtypes. 32 archive specimens of CCA, combined hepatocellular carcinoma-CCA (HCC-CCA) and liver metastasis of PDAC were stained by FOXF1 and CRP immunohistochemistry and evaluated to determine histological pattern. The CCAs were classified radiologically into peripheral/intrahepatic and hilar subtype. Using Fisher exact test, we identified nuclear FOXF1 as a fairly specific (87%) but insensitive (65%) marker of hilar and extrahepatic CCA and metastatic PDAC (p = 0.005). CRP immunohistochemistry was characterized by a high sensitivity and specificity, of 79% and 88%, respectively (p = 0.001). We did not identify any histomorphological features associated with either types of CCA or metastatic PDAC. As a conclusion of novel finding, FOXF1 immunohistochemistry may be regarded as a specific but insensitive marker of hilar/extrahepatic CCA and metastatic PDAC and it may help distinguish them from peripheral CCA.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádory žlučových cest $x metabolismus $x patologie $7 D001650
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a hepatocelulární karcinom $x metabolismus $x patologie $7 D006528
650    _2
$a duktální karcinom slinivky břišní $x metabolismus $x sekundární $7 D021441
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a forkhead transkripční faktory $x metabolismus $7 D051858
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a Klatskinův nádor $x metabolismus $x patologie $7 D018285
650    _2
$a nádory jater $x metabolismus $x sekundární $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory slinivky břišní $x metabolismus $x patologie $7 D010190
650    _2
$a prognóza $7 D011379
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
700    1_
$a Prouzová, Zuzana $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Královské Vinohrady, Prague, Czech Republic
700    1_
$a Mydlíková, Katarína $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Královské Vinohrady, Prague, Czech Republic
700    1_
$a Jedličková, Kristína $u Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Holešta, Michal $u Department of Radiodiagnostics, Charles University, 3rd Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic
700    1_
$a Whitley, Adam $u Department of General Surgery, Charles University, 3rd Faculty of Medicine, Charles University, University Hospital Královské Vinohrady, Prague, Czech Republic
700    1_
$a Havlůj, Lukáš $u Department of General Surgery, Charles University, 3rd Faculty of Medicine, Charles University, University Hospital Královské Vinohrady, Prague, Czech Republic
773    0_
$w MED00180530 $t Pathology oncology research : POR $x 1532-2807 $g Roč. 27, č. - (2021), s. 1609756
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34257615 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131027 $b ABA008
999    __
$a ok $b bmc $g 1789886 $s 1163670
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 27 $c - $d 1609756 $e 20210420 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
LZP    __
$a Pubmed-20220425
Back

Find record

Citation metrics

Archiving options